Raduis Health Inc. (Nasdaq: RDUS) provided promising updated data from a Phase 1 005 clinical study of elacestrant to treat breast cancer. Shares of the biopharmaceutical surged $4.19 to close at $31.60.
Radius Health provides promising data
December 08, 2017 at 17:36 PM EST